In This Article:
NEW YORK, NY / ACCESSWIRE / May 23, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.
PriceSmart, Inc. (PSMT)
Class Period: October 26, 2017 - October 25, 2018
Lead Plaintiff Deadline : July 22, 2019
Join the action: https://www.zlk.com/pslra-1/pricesmart-inc-loss-form?prid=1653&wire=1
The lawsuit alleges: PriceSmart, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) that the Company's omni-channel business strategy had failed to reach key operating goals; (2) that the Company's South America distribution strategy had failed to realize key cost saving goals; (3) that the Company had invested Trinidad and Tobago dollars into certificates of deposits with financial institutions; (4) that these investments had been improperly classified as cash and cash equivalents; (5) that the relevant corrections would materially impact financial statements; (6) that there was a material weakness in the Company's internal controls over financial reporting; (7) that increasing competition negatively impacted the Company's revenue and profitability; and (8) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
To learn more about the PriceSmart, Inc. class action contact jlevi@levikorsinsky.com.
Zogenix, Inc. (ZGNX)
Class Period: February 6, 2019 - April 8, 2019
Lead Plaintiff Deadline : June 11, 2019
Join the action: https://www.zlk.com/pslra-1/zogenix-inc-loss-form?prid=1653&wire=1
The lawsuit alleges that, during the class period, Zogenix, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Zogenix's NDA for FINTEPLA contained inadequate non-clinical data and an incorrect version of a clinical dataset; (ii) consequently, Zogenix's NDA for FINTEPLA was unlikely to gain FDA approval; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more about the Zogenix, Inc. class action contact jlevi@levikorsinsky.com.
Equity Bancshares, Inc. (EQBK)
Class Period: May 11, 2018 - April 22, 2019
Lead Plaintiff Deadline : July 12, 2019
Join the action: https://www.zlk.com/pslra-1/equity-bancshares-inc-loss-form?prid=1653&wire=1